COMP <GO>
JSPR vs SCLX // EV/EBITDA & P/E VALUATION
Jasper Therapeutics Inc. (NASDAQ) VS. Scilex Holding Company (NASDAQ) • 15-METRIC TALLY: JSPR 2
— SCLX 1
■ METRIC PARITY
LAST: $0.53 (-1.26%) • MKT CAP: $17.7M
valuation
—
LAST: $2.06 (-1.43%) • MKT CAP: $17.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JSPR VS. SCLX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JSPR | SCLX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 21.05% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -46.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | SCLX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 14.0 | +30.32 | JSPR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.7M | $17.5M | $206.5K | JSPR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JSPR REV | SCLX REV | JSPR GROSS % | SCLX GROSS % | JSPR FCF | SCLX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $30.3M | — | 98.0% | -$77.2M | $3.7M |
| FY 2024 | $0 | $56.6M | — | 98.0% | -$62.6M | $19.3M |
| FY 2023 | $0 | $46.7M | — | — | -$52.1M | -$20.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JSPR // BETA —
SCLX // BETA —